Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer

Launched by AZIENDA UNITA SANITARIA LOCALE DI PIACENZA · Mar 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of neoadjuvant chemotherapy (NAT) in elderly patients with pancreatic cancer, specifically those aged 70 and older who have tumors that can be surgically removed or are borderline resectable (meaning they are close to being operable but may require more treatment first). The researchers want to find out if receiving chemotherapy before surgery can help patients live longer and have fewer complications compared to having surgery right away. They will also look at how well the chemotherapy works and how it affects the patients' ability to tolerate treatment.

To participate in this study, patients must be 70 years or older and have specific types of pancreatic cancer that can be treated with surgery. They will be selected from hospital records and their treatment outcomes will be compared based on whether they received chemotherapy before surgery or went straight to surgery. This research aims to help doctors better choose the right treatment for elderly patients, with the goal of improving their chances of survival and overall quality of life.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Patients aged ≥ 70 years
• • Patients with resectable or BR PDAC who underwent curative treatment (NAT followed by surgery and upfront surgery)
• • Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \> 2
• • Patients able to provide informed consent, whenever possible
• • Exclusion Criteria
• • Patients not meeting the inclusion criteria.
• • Pancreatic cancer of pancreatic body and tail.
• • Patients with metastatic disease.
• • Patients with locally advanced or metastatic pancreatic cancer